Review
Version 1
Preserved in Portico This version is not peer-reviewed
Safety of Iron Chelation Therapies in Kidney Disease
*
and
Version 1
: Received: 26 May 2023 / Approved: 29 May 2023 / Online: 29 May 2023 (07:26:02 CEST)
How to cite: Nguyen, T.; Wang, Z.A. Safety of Iron Chelation Therapies in Kidney Disease. Preprints 2023, 2023051989. https://doi.org/10.20944/preprints202305.1989.v1 Nguyen, T.; Wang, Z.A. Safety of Iron Chelation Therapies in Kidney Disease. Preprints 2023, 2023051989. https://doi.org/10.20944/preprints202305.1989.v1
Abstract
Background: Iron chelation medications (desferoxamine, desferasirox, desferiprone) are used to manage iron overload. These medications are partially excreted via the kidneys, desferoxamine and desferiprone excretes primarily in the urine, and desferasirox had about 8% excreted in the urine. Their use in severe kidney disease and dialysis patients is caution as “avoided” concerning adverse effects; however, there are reports safe use. This manuscript reviews the literature in this population. Data Sources: Pubmed: desferasirox, deferiprone, deferoxamine, kidney disease, ESKD, Dialysis. Case reports and case series that described experiences with using iron chelation medications in ESKD patients are included. Data also gathered from reading-related sources. Results: This is a review of desferoxamine, desferasirox, and deferiprone use in kidney disease from 1976 to the present time. Table 1 provides a summary of findings. These are mostly reports and brief descriptions of the experiences used in severe kidney disease and dialysis, but lack of randomized control trials and small number of participants. Conclusions: Iron chelation medications are important for treating iron overload but concerns with adverse effects. Due to limited medications available to treat iron overload in patients with severe kidney disease, their safe use has been reporting in the literature. This is an area that warrants further research.
Keywords
Iron chelation; Iron overload; kidney disease; deferoxamine; deferasirox; deferiprone
Subject
Medicine and Pharmacology, Medicine and Pharmacology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
